Welcome
Support Centre
02 September 2010 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   press
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes

[ Print-friendly version ]
A Randomised Trial of Infusional 5-Fluorouracil and Concomitant Radiotherapy in Locally Advanced Rectal Cancer, Comparing Three and Six Months of Infusional 5-Fluorouracil
ISRCTN ISRCTN93845533
ClinicalTrials.gov identifier
Public title A Randomised Trial of Infusional 5-Fluorouracil and Concomitant Radiotherapy in Locally Advanced Rectal Cancer, Comparing Three and Six Months of Infusional 5-Fluorouracil
Scientific title
Acronym N/A
Serial number at source COLORAD
Study hypothesis Not provided at time of registration
Ethics approval Not provided at time of registration
Study design Randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Cancer of rectum
Participants - inclusion criteria 1. Histologically verified adenocarcinoma of the rectum, which is either:
a. Inoperable primary tumour
b. Locally recurrent tumour
c. Residual pelvic disease after resection as assessed either surgically or histopathologically
2. No evidence of metastatic disease
3. No past history of malignancy
4. No previous radiotherapy to the pelvis
5. Normal bone marrow, liver and renal function
6. No concurrent severe or life threatening illness
Participants - exclusion criteria Not provided at time of registration
Anticipated start date 01/01/1990
Anticipated end date 11/11/1994
Status of trial Completed
Patient information material
Target number of participants Not provided at time of registration
Interventions All patients receive continuous infusional 5-fluorouracil for 12 weeks plus radiotherapy to the pelvis, minimum 45 Gy given in twenty-five fractions over 5 weeks to start at the beginning of the 5th week of chemotherapy.

Depending upon the initial randomisation, patients receive either:
1. Group One: Continuous infusional 5-fluorouracil for a further 12 weeks.
2. Group Two: No further chemotherapy with 5-fluorouracil.
Primary outcome measure(s) Not provided at time of registration
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Royal Marsden Hospital (UK)
Trial website
Publications
Contact name Dr  -  -
  Address UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Tel +44 (0) 20 7670 4723
  Fax +44 (0) 20 7670 4818
  Email register@ctu.mrc.ac.uk
Sponsor The Royal Marsden NHS Foundation Trust (UK)
  Address Downs Road
  City/town Sutton
  Zip/Postcode SM2 5PT
  Country United Kingdom
Date applied 19/08/2002
Last edited 29/05/2008
Date ISRCTN assigned 19/08/2002
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2010 ISRCTN unless otherwise stated.


BioMed Central